Advanced Glycation End Products Increase MDM2 Expression via Transcription Factor KLF5

Abstract EN

Type 2 diabetes increases the risk for all-site cancers including colon cancer.

Diabetic patients present typical pathophysiological features including an increased level of advanced glycation end products (AGEs), which comes from a series of nonenzymatic reactions between sugars and biological macromolecules, positively associated with the occurrence of diabetic complications.

MDM2 is an oncogene implicated in cancer development.

The present study investigated whether diabetes promoted MDM2 expression in colon cells and the underlying mechanisms.

Our results showed that AGE increased the protein level of MDM2 in a cell model and promoted binding between MDM2 and Rb as well as p53, which led to degradation of Rb and p53.

KLF5 was able to bind to the regulatory sequence of the MDM2 gene, and knockdown of the KLF5 protein level inhibited the AGE-triggered MDM2 overexpression, which indicated that KLF5 was the transcription factor for MDM2.

In a mouse model of diabetes, we found that AGE level was increased in serum.

The protein levels of both KLF5 and MDM2 were increased.

KLF5 was able to bind to the regulatory sequence of the MDM2 gene.

In conclusion, our results suggest that diabetes increases the level of AGE which enhances the expression of MDM2 via transcription factor KLF5 in colon cells.

MDM2 overexpression is a candidate biological link between type 2 diabetes and colon cancer development.